Search Result

Results for "

CXCR4 antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apelin Receptor (APJ) (3) Apoptosis (2) Arrestin (3) Cadherin (1) Caspase (1) CCR (2) CXCR (61) ERK (1) GSK-3 (1) HIV (28) Isotope-Labeled Compounds (1) P2X Receptor (1) p38 MAPK (1) Reference Standards (1) VEGFR (2) Virus Protease (2)
By Research Areas:	Cancer (41) Cardiovascular Disease (1) Endocrinology (23) Infection (32) Inflammation/Immunology (15)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147808

CXCR4 antagonist 7	CXCR HIV	Infection Inflammation/Immunology Cancer
CXCR4 antagonist 7 (Compound PARA-B) is a *CXCR4* antagonist with the IC₅₀ of 9.3 nM. CXCR4 antagonist 7 can be used for the research of HIV infection, inflammatory diseases, cancer, and WHIM syndrome .

HY-136437

CXCR4 antagonist 1	CXCR HIV	Infection
CXCR4 antagonist 1 is a potent *CXCR4* antagonist. CXCR4 antagonist 1 has anti-HIV activity .

HY-147978

CXCR4 antagonist 8	CXCR	Infection Cancer
CXCR4 antagonist 8 (Compound 3) is a *CXCR4* antagonist with an IC₅₀ of 57 nM. CXCR4 antagonist 8 inhibits CXCL12 induced cytosolic calcium increase with an IC₅₀ of 0.24 nM. CXCR4 antagonist 8 inhibits CXLC12/CXCR4 mediated cell migration .

HY-144286

CXCR4 antagonist 3	CXCR	Infection
CXCR4 antagonist 3 (compound 12a) is a potent antagonist of *CXCR4* with an IC₅₀ of 11 nM. CXCR4 antagonist 3 is a congener of TIQ15. CXCR4 antagonist 3 demonstrates the best overall properties including CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. CXCR4 antagonist 3 has the potential for the research of human immunodeficiency virus .

HY-146401

CXCR4 antagonist 6	CXCR	Cancer
CXCR4 antagonist 6 (compound 46) is a potent *CXCR4* antagonist with an IC₅₀ value of 79 nM. CXCR4 antagonist 6 inhibits CXCL12 induced cytosolic calcium flux (IC₅₀ = 0.25 nM). CXCR4 antagonist 6 significantly mitigates CXCL12/CXCR4 mediated cell migration. CXCR4 antagonist 6 exhibits marked efficacy in a cancer metastasis model in mice .

HY-132936

CXCR4 antagonist 2	CXCR	Others
CXCR4 antagonist 2 is a *CXCR4* antagonist with an IC₅₀ value of 47 nM.

HY-168095

CXCR4 antagonist 10	CXCR	Cancer
CXCR4 antagonist 10 (compound 21) is a potent antagonist of *CXCR4, with the IC₅₀* of 7.8 nM. CXCR4 antagonist 10 plays an important role in cancer research .

HY-147979

CXCR4 antagonist 9	CXCR	Infection Cancer
CXCR4 antagonist 9 (Compound 2) is a *CXCR4* antagonist with an IC₅₀ of 15 nM. CXCR4 antagonist 9 inhibits CXCL12 induced cytosolic calcium increase with an IC₅₀ of 1.3 nM .

HY-146372

CXCR4 antagonist 5	CXCR	Cancer
CXCR4 antagonist 5 (compound 23) is a highly potent *CXCR4* antagonist with an IC₅₀ value of 8.8 nM. CXCR4 antagonist 5 can inhibit CXCL12-induced cytosolic calcium increase (IC₅₀ = 0.02 nM) and inhibits CXCR4/CXLC12-mediated chemotaxis. CXCR4 antagonist 5 has good physicochemical properties and in vitro safety profiles, inhibiting CYP isozymes and hERG marginally or moderately .

HY-144285

CXCR4 antagonist 4	CXCR HIV	Inflammation/Immunology
CXCR4 antagonist 4 is a potent, orally active *CXCR4* antagonist (IC₅₀=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC₅₀=7 nM) .

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting *CXCR4* with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-103009

MSX-127 1 Publications Verification	CXCR	Cancer
MSX-127 is a *CXCR4* antagonist. MSX-127 inhibits cancer metastasis .

HY-103010

MSX-130	CXCR	Cancer
MSX-130 is a *CXCR4* antagonist. MSX-130 inhibits cancer metastasis .

HY-146413

HF50731	CXCR HIV	Infection Cancer
HF50731 (compound 21) is a potent *CXCR4* antagonist. HF50731 shows strong *CXCR4* binding affinity, with IC₅₀ of 19.8 nM. HF50731 effectively inhibits calcium mobilization, cell migration, and HIV-1 infection via CXCR4 coreceptor, with IC₅₀ values of 119.2 nM, 621.4 nM and 1.5 μM .

HY-101458

IT1t	CXCR HIV	Inflammation/Immunology Endocrinology
IT1t is a potent *CXCR4* antagonist; inhibits CXCL12/CXCR4 interaction with an IC₅₀ of 2.1 nM.

HY-101458A

IT1t dihydrochloride 4 Publications Verification	CXCR HIV	Inflammation/Immunology Endocrinology Cancer
IT1t dihydrochloride is a potent *CXCR4* antagonist; inhibits CXCL12/CXCR4 interaction with an IC₅₀ of 2.1 nM.

HY-12488

LY2510924 10+ Cited Publications	CXCR	Endocrinology Cancer
LY2510924 is a potent and selective *CXCR4* antagonist that blocks SDF-1 binding to CXCR4 with an IC₅₀ of 0.079 nM.

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective *CXCR4* antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P1104A

FC131 TFA	CXCR HIV	Infection
FC131 TFA is a *CXCR4* antagonist, inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM. Anti-HIV activity .

HY-13696

MSX-122 1 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
MSX-122 is an orally active partial antagonist of *CXCR4, inhibiting CXCR4/CXCL12* actions, with an IC₅₀ of ∼10 nM. MSX-122 has anti-inflammatory and anti-metastatic activity.

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective *CXCR4* antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-111224

GSK812397	HIV CXCR	Infection
GSK812397 is a CXCR4 antagonist with potential for the treatment of HIV infection. To evaluate the clinical potential of GSK812397, kilogram-scale agent candidates are needed. Here, an improved, scalable synthetic route for the CXCR4 antagonist GSK812397 is described. This new route has been scaled up in a 50-liter stationary facility to obtain 1.2 kg of agent substance in 20% overall yield and >99% chemical and enantiomeric purity in five steps. CXC chemokine receptor 4 (CXCR4) is a 7-transmembrane protein that functions in part as a host co-receptor for multiple strains of HIV-1. It is thought that targeting CXCR4 will help inhibit the replication of several late cytopathic viruses; therefore, CXCR4 antagonists are one of the most promising new classes of experimental anti-HIV agents. GSK812397 is a potent CXCR4 antagonist and is therefore a candidate for investigation for the treatment of HIV infection.

HY-114244

USL311 1 Publications Verification	CXCR	Endocrinology Cancer
USL311 is a potent and selective *CXCR4* antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 .

HY-P10427A

DV1 TFA	CXCR HIV	Infection
DV1 TFA is a selective antagonist for CXC chemokine receptor 4 (CXCR4). DV1 TFA exhibits antiviral activity by blocking HIV-1 entry through the CXCR4 co-receptor .

HY-P1104

FC131	CXCR HIV	Infection
FC131 is a potent *CXCR4* antagonist. FC131 inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4 with an IC₅₀ of 4.5 nM. FC131 has anti-HIV activity .

HY-P10973

Peptide R analogue 10	CXCR ERK	Cancer
Peptide R analogue 10 (compound 10) is an analog of the *CXCR4* antagonist peptide Peptide R (HY-P4111) with stronger antagonistic potency, specificity and plasma stability. Peptide R analogue 10 can inhibit CXCL12-mediated cell migration, ERK phosphorylation and CXCR4 internalization. Peptide R analogue 10 can be used in the study of CXCR4 overexpressing leukemia and colon cancer .

HY-115493

TIQ-15	CXCR	Others
TIQ-15 is a potent *CXCR4* antagonist with an IC₅₀ value of 6 nM for CXCR4 Ca ²⁺ flux. TIQ-15 inhibits CYP450 2D6 with an IC₅₀ value of 0.32 μM .

HY-144347

HF51116	CXCR	Infection Cancer
HF51116 is a potent antagonist of *CXCR4. HF51116 strongly antagonizes SDF-1α-induced cell migration, calcium mobilization, and CXCR4* internalization. HF51116 inhibits HIV-1 infection via CXCR4. HF51116 has the potential for the research of HIV-1 infection, hematopoietic stem cell mobilization, and cancer metastasis .

HY-50912

Plerixafor octahydrochloride Maximum Cited Publications 88 Publications Verification AMD3100 octahydrochloride; JM3100 octahydrochloride; SID791 octahydrochloride	CXCR HIV Virus Protease	Inflammation/Immunology Endocrinology Cancer
Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective *CXCR4* antagonist with an IC₅₀ of 44 nM.

HY-P0171

Motixafortide 3 Publications Verification BKT140 (4-fluorobenzoyl); BL-8040; TF14016	CXCR	Endocrinology Cancer
Motixafortide (BKT140 4-fluorobenzoyl) is a novel *CXCR4* antagonist with an IC₅₀ vakue of ～1 nM.

HY-122058

KRH-3955	HIV	Infection
KRH-3955 is a CXCR4 antagonist with good bioavailability and potent anti-HIV-1 activity. KRH-3955 can effectively inhibit the replication of X4 HIV-1, including clinical isolates from different donors. KRH-3955 also shows activity against recombinant X4 HIV-1 containing reverse transcriptase, protease and tyrosinase resistance mutations. KRH-3955 can inhibit the binding of SDF-1alpha to CXCR4 and calcium ion signaling through this receptor. KRH-3955 inhibits the binding of an antibody against CXCR4 to CXCR4, showing a potent antagonistic effect on CXCR4. KRH-3955 shows an oral bioavailability of 25.6% in rats and can inhibit the replication of X4 HIV-1 in vivo .

HY-P10427

DV1	CXCR HIV	Infection
DV1 is a selective antagonist for CXC chemokine receptor 4 (CXCR4). DV1 exhibits antiviral activity by blocking HIV-1 entry through the CXCR4 co-receptor. DV1 is stable in rat plasma and exhibits good pharmacokinetic characteristics in rat models .

HY-15478

WZ811 3 Publications Verification	CXCR	Endocrinology Cancer
WZ811 is an orally active, highly potent competitive antagonist of *CXCR4. WZ811 efficiently inhibits CXCR4*/SDF-1 (or CXCL12)-mediated modulation of cAMP levels (EC₅₀=1.2 nM) and SDF-1 induced Matrigel invasion in cells (EC₅₀=5.2 nM) .

HY-168531

EMU-116	CXCR	Cancer
EMU-116 is an orally active *CXCR4* antagonist. EMU-116 can be used in the study of cancer .

HY-P10429

RCP168	CXCR	Infection
RCP168 is a highly selective and affinity *CXCR4* receptor antagonist (IC₅₀=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via *CXCR4* receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between *CXCR4* receptor and other chemical factor receptors .

HY-122058A

KRH-3955 hydrochloride	CXCR HIV	Infection Inflammation/Immunology
KRH-3955 hydrochloride is an orally bioavailable *CXCR4* antagonist. KRH-3955 hydrochloride inhibits SDF-1α binding to *CXCR4* with an IC₅₀ of 0.61 nM. KRH-3955 hydrochloride is also a highly potent and selective inhibitor of X4 HIV-1, with an EC₅₀ of 0.3 to 1.0 nM .

HY-P991656

LY-2624587	CXCR Apoptosis p38 MAPK Akt	Cancer
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting *CXCR4. LY-2624587 blocks SDF-1/CXCR4* interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .

HY-19867A

Burixafor hydrobromide 2 Publications Verification TG-0054 hydrobromide	CXCR VEGFR	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Burixafor (TG-0054) hydrobromide is a selective, orally active *CXCR4* antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses .

HY-P7061A

ALX 40-4C Trifluoroacetate 1 Publications Verification	Apelin Receptor (APJ) CXCR	Infection Endocrinology
ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-P7061

ALX 40-4C	CXCR Apelin Receptor (APJ)	Infection Endocrinology
ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-50101A

Mavorixafor trihydrochloride 5+ Cited Publications AMD-070 trihydrochloride; AMD-11070 trihydrochloride	CXCR HIV	Infection Endocrinology Cancer
Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available *CXCR4* antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively.Mavorixafor trihydrochloride can be used for the study of WHIM syndrome .

HY-50101

Mavorixafor 5+ Cited Publications AMD-070; AMD-11070	CXCR HIV	Infection Endocrinology Cancer
Mavorixafor (AMD-070) is a potent, selective and orally available *CXCR4* antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively. Mavorixafor can be used for the study of WHIM syndrome .

HY-50101C

Mavorixafor hydrochloride 5+ Cited Publications AMD-070 hydrochloride; AMD-11070 hydrochloride	CXCR HIV	Infection Cancer
Mavorixafor (AMD-070) hydrochloride is a potent, selective and orally available *CXCR4* antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding. Mavorixafor hydrochloride also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 nM and 9 nM, respectively. Mavorixafor hydrochloride can be used for the study of WHIM syndrome .

HY-15971A

AMD 3465 5 Publications Verification GENZ-644494	CXCR HIV	Infection Endocrinology
AMD 3465 (GENZ-644494) is a potent antagonist of *CXCR4, inhibits binding of 12G5 mAb and CXCL12 ^AF647 to CXCR4, with IC₅₀s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV* strains (IC₅₀: 1-10 nM), but has no effect on CCR5-using (R5) viruses.

HY-50912R

Plerixafor octahydrochloride (Standard)	CXCR HIV Virus Protease	Inflammation/Immunology Endocrinology Cancer
Plerixafor (octahydrochloride) (Standard) is the analytical standard of Plerixafor (octahydrochloride). This product is intended for research and analytical applications. Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic *CXCR4* antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for *CXCR4* than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-15971

AMD 3465 hexahydrobromide 5 Publications Verification GENZ-644494 hexahydrobromide	CXCR HIV	Infection Endocrinology
AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of *CXCR4, inhibits binding of 12G5 mAb and CXCL12 ^AF647 to CXCR4, with IC₅₀s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV* strains (IC₅₀: 1-10 nM), but has no effect on CCR5-using (R5) viruses.

HY-P4111

Peptide R	CXCR	Cancer
Peptide R, a cyclic peptide, is a specific *CXCR4* antagonist. Peptide R shows outstanding capacities to profoundly remodel the tumor stroma. Peptide R has the potential for tumor research .

HY-P10415

EPI-X4 1 Publications Verification hSA(408–423) peptide	CXCR	Infection Inflammation/Immunology Cancer
EPI-X4 (hSA408–423 peptide) is an antagonist for C-X-C motif chemokine receptor 4 (CXCR4) with IC₅₀ of 8.6 μM. EPI-X4 blocks the CXCL12-mediated signaling, inhibits chemokine-mediated migration and invasion of leukemia cell. EPI-X4 exhibits anti-inflammatory activity in mouse model. EPI-X4 exhibits antiviral activity against CXCR4-tropic HIV with IC₅₀ of 8.6 μM .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic *CXCR4* antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for *CXCR4* than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

Cat. No.	Product Name	Target	Research Area

HY-12488

LY2510924 Maximum Cited Publications 12 Publications Verification	CXCR	Endocrinology Cancer
LY2510924 is a potent and selective *CXCR4* antagonist that blocks SDF-1 binding to CXCR4 with an IC₅₀ of 0.079 nM.

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective *CXCR4* antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P1104A

FC131 TFA	CXCR HIV	Infection
FC131 TFA is a *CXCR4* antagonist, inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM. Anti-HIV activity .

HY-168095

CXCR4 antagonist 10	CXCR	Cancer
CXCR4 antagonist 10 (compound 21) is a potent antagonist of *CXCR4, with the IC₅₀* of 7.8 nM. CXCR4 antagonist 10 plays an important role in cancer research .

HY-144285

CXCR4 antagonist 4	CXCR HIV	Inflammation/Immunology
CXCR4 antagonist 4 is a potent, orally active *CXCR4* antagonist (IC₅₀=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC₅₀=7 nM) .

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting *CXCR4* with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective *CXCR4* antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P10427A

DV1 TFA	CXCR HIV	Infection
DV1 TFA is a selective antagonist for CXC chemokine receptor 4 (CXCR4). DV1 TFA exhibits antiviral activity by blocking HIV-1 entry through the CXCR4 co-receptor .

HY-P1104

FC131	CXCR HIV	Infection
FC131 is a potent *CXCR4* antagonist. FC131 inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4 with an IC₅₀ of 4.5 nM. FC131 has anti-HIV activity .

HY-P10973

Peptide R analogue 10	CXCR ERK	Cancer
Peptide R analogue 10 (compound 10) is an analog of the *CXCR4* antagonist peptide Peptide R (HY-P4111) with stronger antagonistic potency, specificity and plasma stability. Peptide R analogue 10 can inhibit CXCL12-mediated cell migration, ERK phosphorylation and CXCR4 internalization. Peptide R analogue 10 can be used in the study of CXCR4 overexpressing leukemia and colon cancer .

HY-P0171

Motixafortide 3 Publications Verification BKT140 (4-fluorobenzoyl); BL-8040; TF14016	CXCR	Endocrinology Cancer
Motixafortide (BKT140 4-fluorobenzoyl) is a novel *CXCR4* antagonist with an IC₅₀ vakue of ～1 nM.

HY-P10427

DV1	CXCR HIV	Infection
DV1 is a selective antagonist for CXC chemokine receptor 4 (CXCR4). DV1 exhibits antiviral activity by blocking HIV-1 entry through the CXCR4 co-receptor. DV1 is stable in rat plasma and exhibits good pharmacokinetic characteristics in rat models .

HY-P10429

RCP168	CXCR	Infection
RCP168 is a highly selective and affinity *CXCR4* receptor antagonist (IC₅₀=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via *CXCR4* receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between *CXCR4* receptor and other chemical factor receptors .

HY-P7061A

ALX 40-4C Trifluoroacetate 1 Publications Verification	Apelin Receptor (APJ) CXCR	Infection Endocrinology
ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-P7061

ALX 40-4C	CXCR Apelin Receptor (APJ)	Infection Endocrinology
ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic *CXCR4* antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for *CXCR4* than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P4111

Peptide R	CXCR	Cancer
Peptide R, a cyclic peptide, is a specific *CXCR4* antagonist. Peptide R shows outstanding capacities to profoundly remodel the tumor stroma. Peptide R has the potential for tumor research .

HY-P10415

EPI-X4 1 Publications Verification hSA(408–423) peptide	CXCR	Infection Inflammation/Immunology Cancer
EPI-X4 (hSA408–423 peptide) is an antagonist for C-X-C motif chemokine receptor 4 (CXCR4) with IC₅₀ of 8.6 μM. EPI-X4 blocks the CXCL12-mediated signaling, inhibits chemokine-mediated migration and invasion of leukemia cell. EPI-X4 exhibits anti-inflammatory activity in mouse model. EPI-X4 exhibits antiviral activity against CXCR4-tropic HIV with IC₅₀ of 8.6 μM .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic *CXCR4* antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for *CXCR4* than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P4111A

Peptide R TFA	CXCR	Cancer
Peptide R (TFA) is a synthetic and specific *CXCR4* antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research .

HY-P1102

TC14012 3 Publications Verification	CXCR HIV	Infection Cancer
TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic *CXCR4* antagonist with an IC₅₀ of 19.3 nM. TC14012 is a potent *CXCR7* agonist with an EC₅₀ of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity .

HY-P1102A

TC14012 TFA	CXCR HIV	Infection Cancer
TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic *CXCR4* antagonist with an IC₅₀ of 19.3 nM. TC14012 TFA is a potent *CXCR7* agonist with an EC₅₀ of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 TFA has anti-HIV activity and anti-cancer activity .

HY-P10971

Nef-M1	CXCR Apoptosis VEGFR GSK-3 Cadherin Caspase	Cancer
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting *CXCR4* and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits VEGF-A, p-GSK-3β and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer .

Cat. No.	Product Name	Target	Research Area

HY-P991656

LY-2624587	CXCR Apoptosis p38 MAPK Akt	Cancer
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting *CXCR4. LY-2624587 blocks SDF-1/CXCR4* interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .

Cat. No.	Product Name	Chemical Structure

HY-10046S

Plerixafor-d4
Plerixafor-d₄ is the deuterium labeled Plerixafor. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC₅₀ of 1-10 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: